Clinical Trial Update: Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of PEG-rhG-CSF to prevent neutropenia in children with cancer undergoing chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pediatric Cancer | Phase 2 | Status: UNKNOWN